Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

The Lancet

Volumn 375, Issue 9721, 2010, Pages 1173-1181

  Bakris, George L ^a   Sarafidis, Pantelis A ^b   Weir, Matthew R ^c   Dahlöf, Björn ^d   Pitt, Bertram ^e   Jamerson, Kenneth ^e   Velazquez, Eric J ^f   Staikos Byrne, Linda ^g   Kelly, Roxzana Y ^g   Shi, Victor ^g   Chiang, Yann Tong ^g   Weber, Michael A ^h  

^a UNIVERSITY OF CHICAGO   (United States)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h SUNY Downstate Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CREATININE;

ADULT; AGED; ANALYSIS; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DENMARK; DIALYSIS; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; FEMALE; FINLAND; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; NORWAY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; SWEDEN; TELECONSULTATION; UNITED STATES;

EID: 77950187294     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)62100-0     Document Type: Article

References (32)

1. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
2. Mancia G., De Backer G., Dominiczak A., et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 25 (2007) 1751-1762
3. Siragy H.M., Xue C., and Webb R.L. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-alpha production after cardiac ischemia. J Cardiovasc Pharmacol 47 (2006) 636-642
4. Zhang X., and Hintze T.H. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 97 (1998) 576-580
5. Sarafidis P.A., Khosla N., and Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 49 (2007) 12-26
6. Khosla N., and Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 1 (2006) 229-235
7. Sarafidis P.A., and Bakris G.L. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 52 (2008) 1749-1757
8. Duka I., and Bakris G. Influence of microalbuminuria in achieving blood pressure goals. Curr Opin Nephrol Hypertens 17 (2008) 457-463
9. Bakris G.L., Fonseca V., Katholi R.E., et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension 46 (2005) 1309-1315
10. Strippoli G.F., Craig M., Deeks J.J., Schena F.P., and Craig J.C. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329 (2004) 828-838
11. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 (2008) 2417-2428
12. Jamerson K.A., Bakris G.L., Wun C.C., et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 17 (2004) 793-801
13. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
14. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288 (2002) 2421-2431
15. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
16. KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 suppl 2 (2007) S12-S154
17. Busby D.E., and Bakris G.L. Comparison of commonly used assays for the detection of microalbuminuria. J Clin Hypertens (Greenwich) 6 suppl 3 (2004) 8-12
18. Campins-Falco P., Sevillano-Cabeza A., and Llobat-Estelles M. Kinetic and chemometric studies of the determination of creatinine using the Jaffe reaction. Part 2. Application to human serum samples: kinetic behaviour and chemometric evaluation of the determination. Analyst 114 (1989) 603-607
19. Lagakos S.W., and Schoenfeld D.A. Properties of proportional-hazards score tests under misspecified regression models. Biometrics 40 (1984) 1037-1048
20. Schoenfeld D.A. Sample-size formula for the proportional-hazards regression model. Biometrics 39 (1983) 499-503
21. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334 (1996) 939-945
22. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006) 131-140
23. Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285 (2001) 2719-2728
24. Bakris G.L., Weir M.R., Shanifar S., et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 163 (2003) 1555-1565
25. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 165 (2005) 936-946
26. Estacio R.O., Jeffers B.W., Gifford N., and Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 suppl 2 (2000) B54-B64
27. Gilbertson D.T., Liu J., Xue J.L., et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16 (2005) 3736-3741
28. Jerums G., Panagiotopoulos S., Premaratne E., Power D.A., and MacIsaac R.J. Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: a pooled analysis. Am J Nephrol 28 (2008) 614-627
29. Levey A.S., Cattran D., Friedman A., et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 54 (2009) 205-226
30. Bakris G.L., Toto R.D., McCullough P.A., Rocha R., Purkayastha D., and Davis P. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 73 (2008) 1303-1309
31. Mishra S.I., Jones-Burton C., Fink J.C., Brown J., Bakris G.L., and Weir M.R. Does dietary salt increase the risk for progression of kidney disease?. Curr Hypertens Rep 7 (2005) 385-391
32. So W.Y., Kong A.P., Ma R.C., et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 29 (2006) 2046-2052